Gusperimus

Gusperimus

Names
Other names N-[2-[4-(3-Aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide[1]
Identifiers
CAS Number	98629-43-7 N
3D model (JSmol)	Interactive image
ChEMBL	ChEMBL406117 Y ChEMBL1172736 Y
ChemSpider	49995 Y 82420 S Y
KEGG	D08032 Y
MeSH	gusperimus
PubChem CID	55362 91272 S
UNII	UJ0ZJ76DO9 Y
CompTox Dashboard (EPA)	DTXSID60861078
InChI InChI=1S/C17H37N7O3/c18-9-7-11-21-10-5-6-12-22-15(26)16(27)24-14(25)8-3-1-2-4-13-23-17(19)20/h16,21,27H,1-13,18H2,(H,22,26)(H,24,25)(H4,19,20,23) Y Key: IDINUJSAMVOPCM-UHFFFAOYSA-N Y
SMILES N=C(N)NCCCCCCC(=O)NC(O)C(=O)NCCCCNCCCN
Properties
Chemical formula	C17H37N7O3
Molar mass	387.529 g·mol−1
log P	−0.933
Acidity (pKa)	11.588
Basicity (pKb)	2.409
Pharmacology
ATC code	L04AA19 (WHO)
Routes of administration	Intravenous Subcutaneous
Pharmacokinetics:
Bioavailability	100%
Legal status	In general: ℞ (Prescription only)
Related compounds
Related compounds	Dibutylhexamethylenediamine Acetyl hexapeptide-3
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). N verify (what is YN ?) Infobox references

Gusperimus is an immunosuppressive drug. It is a derivative of the naturally occurring HSP70 inhibitor spergualin, and inhibits the interleukin-2-stimulated maturation of T cells to the S and G2/M phases and the polarization of the T cells into IFN-gamma-secreting Th1 effector T cells, resulting in the inhibition of growth of activated naive CD4 T cells.

Gusperimus was developed by Bristol-Myers Squibb. Currently, it is manufactured and sponsored for use as an orphan drug and for clinical studies by the Japanese company Euro Nippon Kayaku. The patent claim (see quotation) is that Gusperimus may be useful for a variety of hyperreactive inflammatory diseases such as autoimmune diseases. The drug is available in vials containing 100 mg each.

There is little information about the pharmacokinetic properties of gusperimus.